RxDoctor Payments Data

Douglas Maready, MD

Internal Medicine · Mesa, AZNPI 1689876252

Payments from drug & device makers

$12,205in general payments, 2019–2025

Across 278 payments — averaging $43.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intra-sana Laboratories$7K
  • Novo Nordisk$2K
  • Lilly USA, LLC$629
  • Amgen$483
  • Corcept Therapeutics$451
  • Boehringer Ingelheim$270
  • plus $2K from 25 others

What the payments were for

  • Speaking & faculty fees$6,00049%
  • Food & beverage$5,84548%
  • Education$3613%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,205 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$294,385
Medicare patients
414
Services billed
3,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KorlymMifepristone11$275,331
OzempicSemaglutide85$160,812
JardianceEmpagliflozin84$99,246
MounjaroTirzepatide43$52,048
WegovySemaglutide20$27,174
DescovyEmtricitabine/Tenofov Alafenam11$23,834
EliquisApixaban15$22,446
XareltoRivaroxaban14$18,954
Repatha SureclickEvolocumab11$17,676
ArexvyRsvpref3 Antigen/As01e/Pf53$16,559
TrulicityDulaglutide16$15,816
MyrbetriqMirabegron15$10,958
Tresiba Flextouch U-200Insulin Degludec14$8,547
ShingrixVaricella-Zoster Ge/As01b/Pf38$8,513
Breo ElliptaFluticasone/Vilanterol14$8,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Corcept TherapeuticsKorlym$451$275,33111 claims
Novo NordiskOzempic, Wegovy$1,975$187,987105 claims
Boehringer IngelheimJardiance$270$99,24684 claims
Lilly USA, LLCMounjaro, Trulicity$629$67,86359 claims
GSKArexvy, Shingrix, Breo Ellipta$64$33,144105 claims
PfizerEliquis$107$22,44615 claims
Astellas Pharma US IncMyrbetriq$75$10,95815 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,812183 claims
AbbVieSynthroid$152$83222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →